RetaCalc
Protocol library
SingleApprovedRegulatory LabelSourced

Bremelanotide

A melanocortin receptor agonist with an authorised US auto-injector for a defined indication. Research-vial calculations are not equivalent to the regulated product.

Evidence context, not a personal protocol

Quantities below reproduce study or label context. They do not assess suitability, product equivalence or individual risk.

Regimens studied

Premenopausal women meeting the authorised Vyleesi indication

The label specifies a fixed 1.75 mg subcutaneous auto-injector used when needed, subject to frequency limits

This describes the regulated presentation only and requires the full label and clinical assessment.

View source

Evidence summary

The authorised product uses a fixed-dose device for a defined population. Its efficacy and safety evidence cannot validate a separately sourced research vial.

Safety context

The full label describes transient blood-pressure changes, focal hyperpigmentation, nausea and medicine interactions related to slowed gastric emptying.

Warnings and contraindications

The label limits frequency and includes cardiovascular and pigmentation warnings.
Research-labelled PT-141 is not interchangeable with the authorised auto-injector.

Contraindications reported by the source

Uncontrolled hypertension
Known cardiovascular disease